Request Demo
Last update 24 May 2025
QX-005N
Last update 24 May 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms HDM3016, QX 005N, SNC005 + [1] |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Login to view timeline
Related
19
Clinical Trials associated with QX-005NCTR20241178
一项评价QX005N在中国中度至重度特应性皮炎青少年受试者中的安全性、药代动力学和有效性的临床研究
[Translation] A clinical study evaluating the safety, pharmacokinetics and efficacy of QX005N in Chinese adolescent subjects with moderate to severe atopic dermatitis
CTR20241660
一项评价QX005N在治疗结节性痒疹成人受试者中的有效性和安全性的多中心、随机、双盲、安慰剂对照的III期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of QX005N in the treatment of adult subjects with nodular prurigo
ChiCTR2400082755
A clinical trial evaluating the safety, pharmacokinetics, and efficacy of QX005N in adolescent patients with moderate to severe atopic dermatitis in China - QX005NA-06
100 Clinical Results associated with QX-005N
Login to view more data
100 Translational Medicine associated with QX-005N
Login to view more data
100 Patents (Medical) associated with QX-005N
Login to view more data
100 Deals associated with QX-005N
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| prurigo nodularis | Phase 3 | China | 22 May 2024 | |
| Moderate Atopic Dermatitis | Phase 3 | China | 28 Apr 2024 | |
| Severe Atopic Dermatitis | Phase 3 | China | 28 Apr 2024 | |
| Chronic rhinosinusitis with nasal polyps | Phase 2 | China | 03 Mar 2023 | |
| Pulmonary Disease, Chronic Obstructive | IND Approval | China | 15 Sep 2023 | |
| Asthma | IND Approval | China | 22 Feb 2022 | |
| Chronic Urticaria | IND Approval | China | 27 Jan 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free